Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • AASLD/EASL Symposium: Non-invasive Assessment of Liver Disease

    Contains 5 Component(s) Recorded On: 10/23/2017

    AASLD's AASLD/EASL Symposium presented at The Liver Meeting® 2017.

    The Symposium will provide a broad overview on the diversity of noninvasive diagnostic approaches for assessing chronic liver disease in the U.S. and Europe. Experts will discuss the role and interpretation of noninvasive diagnostic test strategies in assessing the severity of disease associated with NAFLD, cirrhosis, and portal hypertension. These lectures — in conjunction with a panel discussion — will benefit all healthcare professionals using these novel tools in their clinical practice.  

    Jayant A. Talwalker

    Sumeet K. Asrani

    Massimo Pinzani

    Rohit Loomba

    Dr. Rohit Loomba is a Professor of Medicine (with tenure), Director of Hepatology, and Vice Chief, Division of Gastroenterology at University of California at San Diego. He is an internationally recognized thought leader in translational research and innovative clinical trial design in nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH), and non-invasive assessment of steatosis and fibrosis using advanced imaging modalities. Dr. Loomba is the founding director of the UCSD NAFLD Research Center where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome.

    Laurent Castera

  • Basic Research Workshop: A New Era of Gene Editing for Liver Disease

    Product not yet rated Contains 8 Component(s) Recorded On: 10/22/2017

    AASLD's Basic Research Workshop presented at The Liver Meeting® 2017.

    The future is bright for the continued development of novel gene therapy approaches in liver disease. But, a deeper understanding of off-target effects and immune responses generated in host cells by gene carriers is needed to fully realize their potential. This workshop will provide an overview of current and emerging therapeutic gene editing strategies for liver diseases. Speakers will discuss how novel genome editing techniques and designer nucleases offer the ability to carry out sophisticated gene function studies in vivo. In addition, the workshop will look at how the refinement of delivery systems is paving the way for the translation of gene therapy from bench to bedside.

    Clifford Steer

    R. Scott Mclvor

    Wen Xue

    Mark A. Kay

    Christian Mueller

    Lili Wang

    Keith R. Jerome

  • Thomas E. Starzl Transplant SOA: Equity in Access to Organ Allocation

    Product not yet rated Contains 2 Component(s) Recorded On: 10/22/2017

    AASLD's State-of-the-Art Lectures presented at The Liver Meeting® 2017.

    As the U.S. continues to face disparities in organ allocation — due to an imbalance of supply and demand — patients who are on the waitlist for liver transplantation are increasingly at risk. This session will discuss the importance of geographic disparities in liver transplantation as well as various strategies proposed to address this critical issue in healthcare. 

    Julie Heimbach

    John R. Lake

  • Clinical Practice SIG: Best Practices in Clinical Hepatology

    Contains 3 Component(s) Recorded On: 10/22/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Identifying best practices in the difficult management of patients with liver disease in the community outpatient setting is an important topic in clinical hepatology. It is particularly important to look at the approach to patients with non-alcoholic liver disease that are not  candidates for research studies, the management of portal hypertension and portal vein thrombosis, and outpatient intervention and monitoring of patients with cirrhosis and renal insufficiency. The emphasis of this program is to provide tools for community practitioners to develop management strategies for better patient outcomes. Speakers will review a multidisciplinary approach to these problems and demonstrate the benefit of working in a team that — according to the problem in question — may include surgeons, oncologists, hematologists, nephrologists, interventional radiologists and nutrition experts.

    Kris V. Kowdley

    Mitchell L. Shiffman

    Marcelo Kugelmas

  • Cholestatic and Biliary Diseases SIG: Novel Treatment Approached to Cholestatic Liver Diseases: Theory and Practice

    Product not yet rated Contains 9 Component(s) Recorded On: 10/22/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Recently there is an increased interest and effort in targeting novel pathways to treat cholestatic liver diseases.  Up-to-date science is needed on the new therapeutic targets and the early experiences (successes and failures) of clinical trials to foster discussion of these various approaches and identify priorities for future clinical trials. Presentations in this program will be arranged in pairs with the first explaining the science behind why a specific pathway has good targets for treating cholestatic liver disease, followed by a summary of recent clinical trial and other descriptive experiences targeting these pathways. Further discussion after the paired talks will address why drugs did or did not perform as expected in humans, along with planning priorities for future trials.

    Mario Strazzabosco

    Michael Trauner

    Saul J. Karpen

    Marina G. Silveira

    Marlyn J. Mayo

    Gideon Hirschfield

    Bart Staels

    Cynthia Levy

    Cynthia Levy, MD, FAASLD is currently a Professor of Medicine in the Division of Hepatology at the University of Miami Miller School of Medicine. Dr. Levy received her MD from Universidade Federal do Rio de Janeiro, Brazil. She completed an Internal Medicine residency at University of Miami, a Gastroenterology Fellowship at Mayo Clinic, Rochester, and a Transplant Hepatology Fellowship at University of Florida, Gainesville, having received an AASLD Fellowship Award. Dr. Levy is a member of the AASLD Practice Guidelines Committee and of the ABIM Test and Policy Committee on Transplant Hepatology.  At the University of Miami, Dr. Levy is the program director for the Transplant Hepatology Fellowship program and Associate Director for the Schiff Center for Liver Diseases, where she conducts several industry-sponsored and investigator-initiated studies for cholestatic and autoimmune liver diseases.

    James H. Tabibian

  • Public Health/Healthcare Delivery SIG: Methods for Conducting Healthare Delivery Research

    Product not yet rated Contains 5 Component(s) Recorded On: 10/22/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Given recent attention to healthcare reform efforts in the U.S., a greater emphasis is being placed on generating and synthesizing evidence to inform policies affecting the clinical practice of hepatology. In turn, this program will review and teach attendees about the most common research designs and analytic methods associated with the conduct of healthcare delivery research. Specifically, the topics of quality improvement methods, behavioral and health economics research, qualitative mixed-methods approaches, and health disparities research will be reviewed and discussed in depth through a series of interactive lectures and panel-based discussions. Examples based on the field of clinical hepatology and liver transplantation, including relevant peer-reviewed publications, will be highlighted.

    Michael Volk

    Elliot B. Tapper

    Dr. Elliot Tapper is Assistant Professor of Medicine at the University of Michigan Health System. Dr. Tapper’s research aims to improve the outcomes, quality of life and freedom from adverse events for patients with cirrhosis. His efforts focus on delineating quality indicators and developing interventions for the management and prevention of cirrhotic complications. His work on patient-centered, cost-effective diagnostic strategies for elevated liver enzymes have been published in journals including the American Journal of Gastroenterology, Journal of Hepatology, JAMA Internal Medicine, and the New England Journal of Medicine.

    David S. Goldberg

    Jessica L. Mellinger

    Benjamin Cook

  • Acute on Chronic Liver Failure SIG: Management of the Critically Ill Cirrhotic Patient: Improving Multidisciplinary Care and Avoiding…

    Contains 10 Component(s) Recorded On: 10/22/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Patients with acute-on-chronic liver failure frequently present to the ICU for care, and the mortality rate for cirrhotic patients requiring ICU approaches 50 percent.  Unique physiologic characteristics in the patient population warrant specialized, multidisciplinary, approaches to care.  The goal of this program is to further develop dialog between surgeons, hepatologists and intensive care unit teams to better deliver care to this complex patient population by focusing on the complex physiology of chronic liver failure.  In addition, we will devote special attention to areas of controversy in this patient group including initiation of renal replacement therapy, management of alcoholic hepatitis, defining futility and establishing appropriate goals of care.  

    Constantine J. Karvellas

    Dr. Constantine (Dean) Karvellas is an Associate Professor of Medicine (Critical Care Medicine and Gastroenterology/Hepatology) at the University of Alberta and an Adjunct Professor in the School of Public Health Sciences. He has been an attending intensivist in the E. Garner King General Systems Intensive Care Unit since 2009 and is involved with the Liver Transplant program as a Hepatologist. Dr. Karvellas is the only Canadian co-investigator in the NIH-funded United States Acute Liver Failure study group (US ALFSG). He is also a Vice Chair of the Society of Critical Care Medicine (SCCM) Liver management task force and serves as an Associate Editor for the Journal of Hepatology. Dr. Karvellas’ publications reflect his interests in acute liver failure (ALF), acute on chronic liver failure (ACLF), liver transplantation and extracorporeal liver support.

    Julia A. Wendon

    Mitra K. Nadim

    R. Todd Stravitz

    Hugo E. Vargas

    Hugo E. Vargas, MD, FAASLD is a Mayo Clinic Consultant in the Department of Gastroenterology and Hepatology and the Mayo Clinic Transplantation Center. He is the Medical Director for the Office of Clinical Research – Arizona, and a Professor of Medicine in the Mayo Clinic Alix School of Medicine. Dr. Vargas is the Chair of the Clinical Research Subcommittee, and the Vice Chair of the Arizona Research Operations Management Team.  

    Dr. Vargas has authored or coauthored more than 125 peer-reviewed articles. He is a Fellow of the AASLD, AGA, ACG, ASGE and ACP. He has been active in AASLD and has chaired the Annual Meeting Education Committee, Ethics Commiteee and co-chaired the AASLD/IDSA HCV group from 2016 to 2018. 

    Robert S. Rahimi

    Jennifer C. Lai

    Dr. Lai is a transplant hepatologist, on faculty at the University of California, San Francisco.  Her long-term mission is to help patients with end-stage liver disease survive to and thrive after liver transplantation.  Her primary research focuses on integrating core geriatric principles, such as frailty and physical function, into the day-to-day practice of hepatology and transplant medicine to improve the care of her patients.  She is the founder and principal investigator of the Functional Assessment in Liver Transplantation (FrAILT) Study, a multi-center collaboration aimed at investigating the impact of frailty on liver transplant outcomes.  For her work, she has been named a Beeson Scholar in Aging Research by the National Institute on Aging and a Top 40 Under 40 Leader by the San Francisco Business Times.

    Julie Heimbach

    Ayan Sen

    Puneeta Tandon

    Dr. Tandon is an Associate Professor of Medicine, Director of the Cirrhosis Care Clinic and Transplant Hepatologist at the University of Alberta in Edmonton, Alberta, Canada. She completed her Gastroenterology and Hepatology training at the University of Alberta with fellowships at Yale University and the Hospital Clinic in Barcelona. Her clinical practice and research are focused on cirrhosis. Research interests include acute on chronic liver failure and its related complications, sarcopenia, frailty, nutrition, exercise therapy and the early integration of palliative care principles in cirrhosis.

  • General Hepatology Update

    Contains 3 Component(s) Recorded On: 10/22/2017

    AASLD's General Hepatology Update presented at The Liver Meeting® 2017.

    This program will provide evidence-based and practical updates for three common and/or difficult-to-manage conditions: (1) how to select patients with the lowest likelihood of recidivism for liver transplant listing, (2) how to evaluate and manage acute and chronic venous outflow disorders; and (3) how to diagnose, evaluate and involve a multidisciplinary team in the management of patients with acute liver failure.

    Michael R. Lucey

    Dominique C. Vallas

    Robert J. Fontana

  • Transplant Surgery Workshop: Changing Donors, Recipients and Organ Use

    Product not yet rated Contains 8 Component(s) Recorded On: 10/21/2017

    AASLD's Transplant Surgery Workshop presented at The Liver Meeting® 2017.

    This program will look at current political issues related to organ allocation supported by data and an open debate, as well as changes in listing criteria. In addition, speakers will address best practices for the use of marginal livers and innovative treatment options to use such organs.

    Peter L. Abt

    Karen E. Doucette

    Dennis Irwin

    David S. Goldberg

    David J. Reich

    George E. Loss

    Karim Halazun

    Timothy L. Pruett

  • Liver Transplantation and Surgery Transplant SIG: Advances in Hepatocellular Carcinoma Therapy

    Product not yet rated Contains 9 Component(s) Recorded On: 10/21/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Attendees seeking an overview of the current diagnostic and therapeutic modalities available for patients with liver cancer will benefit from Advances in Hepatocellular Carcinoma Therapy. This session will cover a broad range of topics from epidemiology and future disease burden to the emerging role of genomics in the management of liver cancer. Attendees will also receive an overview of the role of surgical resection as well as the current indications for liver transplantation and post-transplant management and recurrence.

    Hashem B. El-Serag

    Julie Heimbach

    Jorge A. Marrero

    Laura M. Kulik

    Anjana A. Pillai

    Karim Halazun

    Vatche G. Agopian

    Mario Strazzabosco

    Neil Mehta